Beyond lymphocyte suppression by tumor-derived cytokines, preclinical studies have demonstrated that inhibiting adenosine receptors can enhance the antitumor activity of CD8 + T cells and NK cells [12, 27]. This evidence concerns the gene CD8A and neoplasm.